In a major development, the Government of India has finalised arrangements with Hyderabad-based vaccine manufacturer Biological-E to reserve 30 crore of COVID-19 vaccine doses for the country. As per reports, these vaccine doses will be manufactured and stockpiled by Biological-E from August to December 2021.
According to sources, the Union Health Ministry of Health would be making an advance payment of Rs 1500 crore to the manufacturer for this purpose.
Among the many vaccine candidates in India, Biological-E is currently undergoing Phase-3 clinical trials. The Covid-19 vaccine Biological E has reportedly shown promising results in Phase 1 and 2 clinical trials. Moreover, the vaccine being developed by Biological-E is a RBD protein sub-unit vaccine and is likely to be available in the next few months.
Currently, the Government of India is encouraging indigenous Vaccine manufacturers by supporting them in Research and Development (R&D) and financial aid to meet the vaccine demand of the country.
Published: Sanchita Mondal
Last updated: 04 June 2021, 01:50 PM IST
The golden triangle is no more the pole star for tourists. Odisha takes a backseat in fort tourism when it's a trending craze among the visitors - domestic and foreign